StemRIM Inc. (JP:4599) has released an update.
StemRIM Inc., a biotech venture focused on ‘Regeneration-Inducing Medicine’, reported a significant decline in operating revenue and profits for the fiscal year ended July 31, 2024, compared to the previous year. This decrease is attributed to the absence of milestone income from the global Phase 2 clinical trial of Redasemtide for Ischemic Stroke, which had contributed to the previous fiscal year’s results. The company’s innovative approach aims at harnessing the body’s stem cells for tissue repair and regeneration without using living cells or tissues.
For further insights into JP:4599 stock, check out TipRanks’ Stock Analysis page.
